FDA Import Alert Attorney: Detention Without Physical Examination and How to Fight Back
An FDA import alert can choke a business long before a courtroom ever gets involved. Shipments stall. Inventory planning collapses. Distributors get nervous. Customers start looking elsewhere. And management quickly learns that what looked like an isolated border problem may actually be a broader FDA enforcement issue.
If your product or firm has been placed on an import alert, or if shipments are being held under detention without physical examination (DWPE), you need more than customs logistics. You need a regulatory and defense strategy.
What is an FDA import alert?
FDA uses import alerts to identify products and firms that appear to be violating FDA law. Once a product is subject to an applicable alert, future shipments can be detained without FDA having to sample or physically examine each one.
That is what makes import alerts so disruptive. FDA can act based on the “appearance standard,” meaning the agency has authority to refuse products that appear to violate FDA requirements.
What does DWPE mean?
DWPE stands for detention without physical examination. In practical terms, it means shipments are presumed to be problematic unless the importer or owner overcomes that presumption.
This flips the normal business dynamic. Instead of moving goods and dealing with isolated holds, the company now has to prove why the shipment should be released and, in the longer term, why the firm or product should come off the alert altogether.
Why companies get hit with import alerts
Import alerts can stem from many problems, including:
- adulteration,
- misbranding,
- CGMP failures,
- contamination,
- unapproved drug or biologic issues,
- false or misleading labeling,
- API quality concerns,
- country-, manufacturer-, or product-specific enforcement histories.
Sometimes the import alert reflects one shipment. Sometimes it reflects a broader pattern FDA believes it sees in the company’s operations.
What removal from an import alert usually requires
FDA’s removal process is not just a formality. The agency looks for evidence that the conditions leading to DWPE have been resolved and that future shipments will be compliant.
In most cases that means showing:
- investigation of the underlying issue,
- corrective action,
- preventive action,
- proof that the problem will not recur,
- evidence supporting removal, which may include multiple clean shipments, third-party audits, testing, or other documentation.
The totality of evidence matters. A weak petition that merely denies the problem may delay relief and deepen FDA skepticism.
Short-term release vs. long-term removal
These are related but distinct goals.
Shipment release
For an individual detained shipment, the immediate question is whether you can overcome the appearance of the violation with adequate evidence.
Import alert removal
For long-term business continuity, the broader goal is removal from DWPE or movement to a green-list status where applicable.
A sound strategy needs to address both.
Why import alerts are often bigger than import alerts
Import action is frequently a symptom of a larger compliance issue. The agency may be concerned about the manufacturer, the API source, the labeling, the distribution chain, or the product category itself. In some cases, import problems overlap with warning letters, compounding concerns, GLP-1 enforcement, misbranding theories, or potential criminal exposure.
That is why import-alert defense should not be siloed from the rest of the FDA risk analysis.
Why Ronald W. Chapman II is a strong fit for FDA import alert defense
Ronald W. Chapman II brings the mix of regulatory understanding and enforcement defense that import-alert matters often require. He is a former federal prosecutor and U.S. Marine Corps Judge Advocate with an LL.M. in Health Care Law. He represents healthcare-related businesses and other regulated entities in high-stakes federal matters where compliance problems can quickly turn into civil or criminal pressure.
That perspective matters in import cases because the business wants more than shipment release. It wants a durable solution that protects the supply chain without creating unnecessary admissions or overlooking related enforcement exposure.
At Chapman, Dowling & Mallek, import-alert defense means identifying the real FDA concern, building a credible evidentiary response, coordinating technical remediation, and positioning the company for both release and longer-term removal.
FAQ
Does every detained shipment mean we are on an import alert?
No. But repeated holds or holds tied to a listed alert should be treated urgently.
Can we get off an import alert quickly?
Sometimes, but it depends on the underlying issue and the strength of the evidence presented.
Do import alerts apply only to foreign manufacturers?
No. The consequences can affect foreign manufacturers, U.S. importers, distributors, and others in the chain.
Call to action: If your shipments are being detained or your product appears on an FDA import alert, early legal coordination can save months of avoidable disruption.